Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).

Lisa Richters,Oleg Gluz,Nana Weber-Lassalle,Matthias Christgen,Heinz Haverkamp,S. Kuemmel,Mohamad Kayali,Ronald E. Kates,Eva Maria Grischke,Michael Braun,Mathias Warm,Rachel Wuerstlein,Corinna Ernst,Monika Graeser,Jan Hauke,Ulrike Nitz,Hans Kreipe,Rita K. Schmutzler,Eric Hahnen,Nadia Harbeck

Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).

2021

579Background: The phase II trial WSG-ADAPT TN randomized triple-negative breast cancer (TNBC) patients to receive 12 weeks of neoadjuvant nab-paclitaxel (nab-pac) combined with carboplatin (carbo)...

Keywords:

Internal medicine
Medicine
Chemotherapy
in patient
Oncology
Pathological
complete response
Breast cancer
Carboplatin
Triple-negative breast cancer

Correction
Source
Cite
Save

References

Citations